LT3119757T - Diacilglicerolio aciltransferazės 2 inhibitoriai, skirti panaudoti metabolinių ir susijusių ligų gydyme - Google Patents

Diacilglicerolio aciltransferazės 2 inhibitoriai, skirti panaudoti metabolinių ir susijusių ligų gydyme

Info

Publication number: LT3119757T
Authority: LT; Lithuania
Prior art keywords: metabolic; inhibitors; treatment; related disorders; diacylglycerol acyltransferase
Prior art date: 2014-03-17

Application number

LTEP15710006.6T

Other languages

English (en)

Inventor

Shawn Cabral

Kentaro Futatsugi

David Hepworth

Kim HUARD

Daniel Wei-Shung Kung

Suvi Tuula Marjukka Orr

Kun SONG

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-17

Filing date

2015-03-03

Publication date

2018-07-10

2015-03-03 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

2018-07-10 Publication of LT3119757T publication Critical patent/LT3119757T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Obesity (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Child & Adolescent Psychology (AREA)
Immunology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)

LTEP15710006.6T 2014-03-17 2015-03-03 Diacilglicerolio aciltransferazės 2 inhibitoriai, skirti panaudoti metabolinių ir susijusių ligų gydyme LT3119757T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201461954351P	2014-03-17	2014-03-17
PCT/IB2015/051560 WO2015140658A1 (en)	2014-03-17	2015-03-03	Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders

Publications (1)

Publication Number	Publication Date
LT3119757T true LT3119757T (lt)	2018-07-10

Family

ID=52682788

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP15710006.6T LT3119757T (lt)	2014-03-17	2015-03-03	Diacilglicerolio aciltransferazės 2 inhibitoriai, skirti panaudoti metabolinių ir susijusių ligų gydyme

Country Status (39)

Country	Link
US (3)	US9440949B2 (lt)
EP (1)	EP3119757B1 (lt)
JP (1)	JP6152229B2 (lt)
KR (1)	KR101772836B1 (lt)
CN (1)	CN106103425A (lt)
AP (1)	AP2016009407A0 (lt)
AR (1)	AR099768A1 (lt)
AU (1)	AU2015233094B2 (lt)
CA (1)	CA2942759C (lt)
CL (1)	CL2016002169A1 (lt)
CR (1)	CR20160405A (lt)
CU (1)	CU24395B1 (lt)
CY (1)	CY1120354T1 (lt)
DK (1)	DK3119757T3 (lt)
DO (1)	DOP2016000248A (lt)
EA (1)	EA032356B1 (lt)
EC (1)	ECSP16072034A (lt)
ES (1)	ES2674240T3 (lt)
GE (2)	GEAP201814268A (lt)
HR (1)	HRP20180992T1 (lt)
HU (1)	HUE039446T2 (lt)
IL (1)	IL247809A0 (lt)
LT (1)	LT3119757T (lt)
MA (1)	MA39753B1 (lt)
MD (1)	MD20160099A2 (lt)
MX (1)	MX2016012008A (lt)
NI (1)	NI201600129A (lt)
PE (1)	PE20161368A1 (lt)
PH (1)	PH12016501654A1 (lt)
PL (1)	PL3119757T3 (lt)
PT (1)	PT3119757T (lt)
RS (1)	RS57384B1 (lt)
SG (1)	SG11201606779RA (lt)
SI (1)	SI3119757T1 (lt)
SV (1)	SV2016005279A (lt)
TR (1)	TR201809388T4 (lt)
TW (1)	TWI551596B (lt)
UY (1)	UY36033A (lt)
WO (1)	WO2015140658A1 (lt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI3119757T1 (en) *	2014-03-17	2018-08-31	Pfizer Inc.	Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
AR109179A1 (es) *	2016-08-19	2018-11-07	Pfizer	Inhibidores de diacilglicerol aciltransferasa 2
CA3040637C (en) *	2016-10-17	2023-02-28	Keio University	Undifferentiated stem cell-removing agent, and method for removing undifferentiated stem cells
CN116139138A (zh) *	2016-11-11	2023-05-23	3-V生物科学股份有限公司	脂质合成的杂环调节剂
GB201815018D0 (en) *	2018-09-14	2018-10-31	Univ Oxford Innovation Ltd	Enantiomeric compounds
CN110305966B (zh) *	2019-06-18	2023-03-28	广西壮族自治区水产科学研究院	一种罗非鱼肝脏dgat2基因表达的调控方法
TWI771766B (zh) *	2019-10-04	2022-07-21	美商輝瑞股份有限公司	二醯基甘油醯基轉移酶２抑制劑
MX2022007810A (es) *	2019-12-23	2022-07-19	Lg Chemical Ltd	Derivado de amida novedoso util como inhibidor de diacilglicerol aciltransferasa 2, y uso del mismo.
WO2021133035A1 (ko) *	2019-12-23	2021-07-01	주식회사 엘지화학	디아실글리세롤 아실트랜스퍼라제 2 억제제로서 유용한 신규 아미노 아릴 유도체 및 이의 용도
WO2021161222A1 (en) *	2020-02-11	2021-08-19	Inorbit Therapeutics Ab	Compounds useful in inhibiting diacylglycerol o-acyltransferase and methods of making and using the same
JP2022058085A (ja)	2020-02-24	2022-04-11	ファイザー・インク	ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
US11478533B2 (en)	2020-04-27	2022-10-25	Novo Nordisk A/S	Semaglutide for use in medicine
EP4153596A4 (en)	2020-05-18	2024-08-14	Merck Sharp & Dohme LLC	NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS
TWI817191B (zh) *	2020-09-04	2023-10-01	南韓商Ｌｇ化學股份有限公司	新穎聯芳基衍生物及其作為針對二醯基甘油醯基轉移酶２之抑制劑之用途
TW202229243A (zh)	2020-10-08	2022-08-01	美商默沙東藥廠	作為新穎二醯基甘油酯o-醯基轉移酶2抑制劑之苯并咪唑酮衍生物的製備
PE20240217A1 (es)	2020-10-08	2024-02-16	Merck Sharp And Dohme Llc	Preparacion de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2
US12540132B2 (en)	2020-12-22	2026-02-03	Merck Sharp & Dohme Llc	Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors
WO2023026180A1 (en)	2021-08-26	2023-03-02	Pfizer Inc.	Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
IL321166A (en)	2022-12-02	2025-07-01	Merck Sharp & Dohme Llc	Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
US12303604B1 (en)	2024-10-16	2025-05-20	Currax Pharmaceuticals Llc	Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1146866A (en)	1979-07-05	1983-05-24	Yamanouchi Pharmaceutical Co. Ltd.	Process for the production of sustained release pharmaceutical composition of solid medical material
EP0028489B1 (en)	1979-11-05	1983-10-05	Beecham Group Plc	Enzyme derivatives, and their preparation
DE3438830A1 (de)	1984-10-23	1986-04-30	Rentschler Arzneimittel	Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
JP2527107B2 (ja)	1991-04-16	1996-08-21	日本新薬株式会社	固体分散体の製造方法
US5340591A (en)	1992-01-24	1994-08-23	Fujisawa Pharmaceutical Co., Ltd.	Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja)	1992-03-12	2002-03-11	大正製薬株式会社	経口製剤用組成物
US5612359A (en)	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
DE19504832A1 (de)	1995-02-14	1996-08-22	Basf Ag	Feste Wirkstoff-Zubereitungen
TW536540B (en)	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PT901786E (pt)	1997-08-11	2007-08-07	Pfizer Prod Inc	Disperções farmacêuticas sólidas com biodisponibilidade melhorada
CN1149196C (zh)	1998-07-06	2004-05-12	布里斯托尔-迈尔斯斯奎布公司	作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺
MY125533A (en)	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
CA2439152C (en)	2001-02-28	2008-06-17	Merck & Co., Inc.	Acylated piperidine derivatives as melanocortin-4 receptor agonists
PL372887A1 (en)	2002-02-27	2005-08-08	Pfizer Products Inc.	Acc inhibitors
AR044152A1 (es)	2003-05-09	2005-08-24	Bayer Corp	Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
US7320992B2 (en)	2003-08-25	2008-01-22	Amgen Inc.	Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
GB0322409D0 (en)	2003-09-25	2003-10-29	Astrazeneca Ab	Quinazoline derivatives
US7241773B2 (en)	2003-12-22	2007-07-10	Abbott Laboratories	3-quinuclidinyl heteroatom bridged biaryl derivatives
JP2007535553A (ja)	2004-04-29	2007-12-06	アボット・ラボラトリーズ	アミノ−テトラゾール類縁体および使用方法
CA2566108C (en)	2004-05-12	2010-04-06	Pfizer Products Inc.	Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
BRPI0510273A (pt)	2004-05-25	2007-10-30	Pfizer Prod Inc	derivados de tetraazabenzo[e]azuleno e análogos destes
PA8660701A1 (es)	2005-02-04	2006-09-22	Pfizer Prod Inc	Agonistas de pyy y sus usos
NL2000581C2 (nl)	2006-04-20	2008-01-03	Pfizer Prod Inc	Aangecondenseerde fenylamidoheterocyclische verbindingen.
CA2670422C (en)	2006-11-29	2011-09-06	Pfizer Products Inc.	Spiroketone acetyl-coa carboxylase inhibitors
AR070301A1 (es)	2007-05-08	2010-03-31	Otsuka Pharma Co Ltd	Compuesto epoxi y metodo para producir el mismo
US20090036425A1 (en)	2007-08-02	2009-02-05	Pfizer Inc	Substituted bicyclolactam compounds
US8299051B2 (en)	2008-05-13	2012-10-30	Southern Methodist University	Beta-lactamase inhibitory compounds
CA2724774C (en)	2008-05-28	2013-06-25	Pfizer Inc.	Pyrazolospiroketone acetyl-coa carboxylase inhibitors
CA2724603A1 (en)	2008-05-28	2009-12-03	Pfizer Inc.	Pyrazolospiroketone acetyl-coa carboxylase inhibitors
CA2729581A1 (en)	2008-07-29	2010-02-04	Pfizer Inc.	Fluorinated heteroaryls
WO2010022055A2 (en) *	2008-08-20	2010-02-25	Amgen Inc.	Inhibitors of voltage-gated sodium channels
EP2334687B9 (en)	2008-08-28	2012-08-08	Pfizer Inc.	Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
KR20110060904A (ko)	2008-09-26	2011-06-08	베링거 인겔하임 인터내셔날 게엠베하	Ｃｃｒ1 수용체 길항제로서의 아자인다졸 화합물
DE102008053240A1 (de)	2008-10-25	2010-04-29	Saltigo Gmbh	Herstellung von (N-Heterozyklyl)-Arylethern
US8324385B2 (en) *	2008-10-30	2012-12-04	Madrigal Pharmaceuticals, Inc.	Diacylglycerol acyltransferase inhibitors
TW201038580A (en)	2009-02-02	2010-11-01	Pfizer	4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
WO2010100050A1 (en)	2009-03-05	2010-09-10	F. Hoffmann-La Roche Ag	Pyridine-2-yl-carboxylic acid amides
EP2406230A1 (en)	2009-03-11	2012-01-18	Pfizer Inc.	Substituted indazole amides and their use as glucokinase activators
UA99882C2 (uk)	2009-03-11	2012-10-10	Пфайзер Інк.	Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
JP2012520868A (ja)	2009-03-20	2012-09-10	ファイザー・インク	３−オキサ−７−アザビシクロ［３．３．１］ノナン
CA2759891A1 (en)	2009-05-08	2010-11-11	Pfizer Inc.	Gpr 119 modulators
CA2759843A1 (en)	2009-05-08	2010-11-10	Pfizer Inc.	Gpr 119 modulators
JP2012528847A (ja)	2009-06-05	2012-11-15	ファイザー・インク	Ｇｐｒ１１９調節因子としてのｌ−（ピペリジン−４−イル）−ピラゾール誘導体
ES2444777T3 (es) *	2009-06-12	2014-02-26	Bristol-Myers Squibb Company	Compuestos de nicotinamida útiles como moduladores de quinasas
WO2011005611A1 (en)	2009-07-09	2011-01-13	Merck Sharp & Dohme Corp.	Neuromedin u receptor agonists and uses thereof
WO2012024179A1 (en) *	2010-08-18	2012-02-23	Merck Sharp & Dohme Corp.	Substituted amide derivatives as dgat-1 inhibitors
CN103687855A (zh) *	2011-06-02	2014-03-26	英特维特国际股份有限公司	咪唑衍生物
WO2013068328A1 (en) *	2011-11-07	2013-05-16	Intervet International B.V.	Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
AP2014007953A0 (en) *	2012-04-06	2014-09-30	Pfizer	Diacylglycerol acyltransferase 2 inhibitors
SI3119757T1 (en) *	2014-03-17	2018-08-31	Pfizer Inc.	Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders

2015
- 2015-03-03 SI SI201530300T patent/SI3119757T1/en unknown
- 2015-03-03 CA CA2942759A patent/CA2942759C/en active Active
- 2015-03-03 HU HUE15710006A patent/HUE039446T2/hu unknown
- 2015-03-03 AP AP2016009407A patent/AP2016009407A0/en unknown
- 2015-03-03 SG SG11201606779RA patent/SG11201606779RA/en unknown
- 2015-03-03 CR CR20160405A patent/CR20160405A/es unknown
- 2015-03-03 GE GEAP201814268A patent/GEAP201814268A/en unknown
- 2015-03-03 EP EP15710006.6A patent/EP3119757B1/en active Active
- 2015-03-03 AU AU2015233094A patent/AU2015233094B2/en not_active Ceased
- 2015-03-03 EA EA201600589A patent/EA032356B1/ru not_active IP Right Cessation
- 2015-03-03 DK DK15710006.6T patent/DK3119757T3/en active
- 2015-03-03 CU CU2016000125A patent/CU24395B1/es unknown
- 2015-03-03 PE PE2016001618A patent/PE20161368A1/es unknown
- 2015-03-03 LT LTEP15710006.6T patent/LT3119757T/lt unknown
- 2015-03-03 GE GEAP201514268A patent/GEP20186864B/en unknown
- 2015-03-03 PT PT157100066T patent/PT3119757T/pt unknown
- 2015-03-03 TR TR2018/09388T patent/TR201809388T4/tr unknown
- 2015-03-03 ES ES15710006.6T patent/ES2674240T3/es active Active
- 2015-03-03 MD MDA20160099A patent/MD20160099A2/ro not_active Application Discontinuation
- 2015-03-03 PL PL15710006T patent/PL3119757T3/pl unknown
- 2015-03-03 WO PCT/IB2015/051560 patent/WO2015140658A1/en not_active Ceased
- 2015-03-03 JP JP2016557229A patent/JP6152229B2/ja active Active
- 2015-03-03 MA MA39753A patent/MA39753B1/fr unknown
- 2015-03-03 HR HRP20180992TT patent/HRP20180992T1/hr unknown
- 2015-03-03 MX MX2016012008A patent/MX2016012008A/es unknown
- 2015-03-03 KR KR1020167025070A patent/KR101772836B1/ko not_active Expired - Fee Related
- 2015-03-03 CN CN201580014031.5A patent/CN106103425A/zh active Pending
- 2015-03-03 RS RS20180758A patent/RS57384B1/sr unknown
- 2015-03-10 US US14/643,210 patent/US9440949B2/en active Active
- 2015-03-16 TW TW104108356A patent/TWI551596B/zh not_active IP Right Cessation
- 2015-03-16 UY UY0001036033A patent/UY36033A/es not_active Application Discontinuation
- 2015-03-16 AR ARP150100790A patent/AR099768A1/es unknown
2016
- 2016-06-27 US US15/193,440 patent/US9789110B2/en active Active
- 2016-08-18 PH PH12016501654A patent/PH12016501654A1/en unknown
- 2016-08-29 CL CL2016002169A patent/CL2016002169A1/es unknown
- 2016-09-05 NI NI201600129A patent/NI201600129A/es unknown
- 2016-09-07 EC ECIEPI201672034A patent/ECSP16072034A/es unknown
- 2016-09-14 IL IL247809A patent/IL247809A0/en unknown
- 2016-09-16 SV SV2016005279A patent/SV2016005279A/es unknown
- 2016-09-16 DO DO2016000248A patent/DOP2016000248A/es unknown
2017
- 2017-09-01 US US15/693,785 patent/US10188653B2/en active Active
2018
- 2018-06-20 CY CY20181100643T patent/CY1120354T1/el unknown

Also Published As

Publication number	Publication date
PH12016501654A1 (en)	2017-02-06
TR201809388T4 (tr)	2018-07-23
DK3119757T3 (en)	2018-06-18
CY1120354T1 (el)	2019-07-10
TWI551596B (zh)	2016-10-01
SV2016005279A (es)	2017-07-28
US9440949B2 (en)	2016-09-13
MA39753B1 (fr)	2018-10-31
PE20161368A1 (es)	2016-12-25
PL3119757T3 (pl)	2018-09-28
MA39753A (fr)	2017-01-25
MX2016012008A (es)	2016-12-07
ECSP16072034A (es)	2017-05-31
NI201600129A (es)	2016-11-18
JP6152229B2 (ja)	2017-06-21
DOP2016000248A (es)	2017-03-31
HRP20180992T1 (hr)	2018-08-10
SG11201606779RA (en)	2016-10-28
GEAP201814268A (en)	2018-02-12
US10188653B2 (en)	2019-01-29
CA2942759C (en)	2018-01-09
CA2942759A1 (en)	2015-09-24
AU2015233094A1 (en)	2016-09-01
AR099768A1 (es)	2016-08-17
US20180042926A1 (en)	2018-02-15
US9789110B2 (en)	2017-10-17
EP3119757A1 (en)	2017-01-25
US20160303125A1 (en)	2016-10-20
RS57384B1 (sr)	2018-09-28
UY36033A (es)	2015-10-30
KR20160115997A (ko)	2016-10-06
CR20160405A (es)	2016-11-07
EA032356B1 (ru)	2019-05-31
PT3119757T (pt)	2018-06-22
CU20160125A7 (es)	2017-01-10
WO2015140658A1 (en)	2015-09-24
CL2016002169A1 (es)	2017-02-24
US20150259323A1 (en)	2015-09-17
MD20160099A2 (ro)	2017-02-28
CN106103425A (zh)	2016-11-09
AU2015233094B2 (en)	2017-04-27
JP2017507979A (ja)	2017-03-23
HUE039446T2 (hu)	2018-12-28
IL247809A0 (en)	2016-11-30
AP2016009407A0 (en)	2016-08-31
CU24395B1 (es)	2019-04-04
TW201538495A (zh)	2015-10-16
KR101772836B1 (ko)	2017-08-29
ES2674240T3 (es)	2018-06-28
SI3119757T1 (en)	2018-08-31
GEP20186864B (en)	2018-06-25
EA201600589A1 (ru)	2017-03-31
EP3119757B1 (en)	2018-05-16

Publication	Publication Date	Title
IL247809A0 (en)	2016-11-30	Inhibitors of diacylglycerol acyltransferase-2 and their use in the treatment of metabolic diseases
IL251066B (en)	2021-06-30	Preparations and methods for the treatment of metabolic disorders
ZA201700311B (en)	2019-06-26	Compositions and methods of use for treating metabolic disorders
IL290150A (en)	2022-03-01	Compounds and methods for treating chronic pain
EP3183005A4 (en)	2018-01-10	Methods and compositions for the treatment of metabolic disorders
GB201411496D0 (en)	2014-08-13	Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
PL3485890T3 (pl)	2023-08-28	Inhibitory SGLT2 do leczenia zaburzeń metabolicznych u zwierząt psowatych
IL247589A0 (en)	2016-11-30	Dihydropyridine mgat2 inhibitors for use in the treatment of metabolic disorders
PL3160464T3 (pl)	2018-12-31	6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych
SG11201608397UA (en)	2016-11-29	Glyt1 inhibitors for use in the treatment of hematological disorders
IL275349A (en)	2020-07-30	Use of hM4Di in the treatment of seizure disorders
PT3177599T (pt)	2020-03-05	Análogos fumarato e utilizações dos mesmos no tratamento de uma doença autoimune ou uma doença inflamatória
IL258316A (en)	2018-06-28	A combination of trazodone and gabapentin for the treatment of pain
IL248494A0 (en)	2016-12-29	Methods and compositions for the treatment of fat storage diseases
IL251407A0 (en)	2017-05-29	A multivalent compound for the treatment and prevention of brain damage
HK1234656A1 (en)	2018-02-23	Methods and compositions for treatment of lipid storage disorders